Products for Research Use Only
RegisterLogin

Cudetaxestat

CAT: 0804-HY-145561-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145561-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cudetaxestat (BLD-0409; PAT-409) is an orally active and noncompetitive autotaxin (ATX) inhibitor. Cudetaxestat inhibits the activity of ATX, reduces the production of LPA, and thereby blocks the signal transduction of the ATX-LPA axis. Cudetaxestat can still maintain nanomolar-level biochemical efficacy even when the concentration of the LPC substrate increases. Cudetaxestat can be used for the study of various diseases related to LPA including fibrosis, tumor metastasis, inflammation and autoimmune diseases, etc[1][2].
CAS Number
1782070-21-6
Product Name Alternative
BLD-0409; PAT-409
UNSPSC
12352005
Target
LPL Receptor; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cudetaxestat.html
Purity
98.32
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=C(F)C(SC2=C(N(C3=C2C=CC(Cl)=C3F)C4=CN(CCC)N=C4)Cl)=CC=C1)O
Molecular Formula
C21H15Cl2F2N3O2S
Molecular Weight
482.33
References & Citations
[1]Tan Z, et al. An updated patent review of autotaxin inhibitors (2017-present) . Expert Opin Ther Pat. 2021;31 (5) :421-434. |[2]Wong, Carol, et al. Differentiating characteristics of cudetaxestat (BLD-0409), a non-competitive autotaxin inhibitor under development to treat idiopathic pulmonary fibrosis. D29. Mechanisms In Lung Injury, Repair, And Fibrosis. American Thoracic Society, 2022. A5234-A5234.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Autotaxin

Alternative Products

CatalogName
T63190-01Cudetaxestat

Popular Products